
RANI Stock Forecast & Price Target
RANI Analyst Ratings
Bulls say
Rani Therapeutics Hldgs is positioned favorably because its RaniPill platform has repeatedly shown clinically meaningful oral delivery across four studies and more than 250 capsules, with RT-114 achieving greater than 150% relative bioavailability versus matched subcutaneous dosing and no serious or capsule-attributed adverse events. That human PK validation materially de-risks the core technology, while the broader dataset across peptides, proteins, antibodies, and large payloads suggests the platform could support multiple partnered programs rather than a single asset. Financially, the company looks adequately funded for near-term catalysts, ending June with $53.4 million in cash, cash equivalents and marketable securities, while R&D of $5.0 million and EPS of $(0.04) were both better than FactSet expectations, supporting execution through the planned YE26 and 2027 milestones.
Bears say
Rani Therapeutics Hldgs is viewed negatively because the core investment case still depends on an unproven human pharmacodynamic link: while the company has built a compelling human PK dataset, it has not yet shown that RaniPill-delivered exposure produces meaningful efficacy in humans. The evidence base remains limited by small cohorts and short-duration studies, leaving uncertainty around repeat-dose tolerability, durability, and the magnitude of benefit in RT-114 Phase 1b. Even if the platform works technically, commercialization remains uncertain versus increasingly convenient injectable alternatives, and the company’s history of capital constraints and shifting priorities makes scaling dependent on securing partners or additional funding.
This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.
RANI Analyst Forecast & Price Prediction
Start investing in RANI
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Rani Therapeutics Holdings (RANI) Forecast
RANI Analyst Forecast & Price Prediction
Start investing in RANI
Order type
Buy in
Order amount
Est. shares
0 shares